No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 8 of the 30 quarters in the window, leaving 22 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 6.5x · 10Y median 17.8x · 24th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 31
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T21:48:33.398Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T21:48:33.398Z. Latest historical point 2023-05-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T21:48:33.398Z. Latest historical point 2023-08-04. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T21:48:33.398Z. Latest historical point 2023-08-04. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T21:48:33.398Z. Latest historical point 2023-05-08.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T21:48:33.398Z. Latest historical point 2023-05-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T21:48:33.398Z. Latest historical point 2023-08-04. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T21:48:33.398Z. Latest historical point 2023-08-04. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Vir Biotechnology, Inc. (VIR) stock was $11.60 as of Oct 6, 2026, 4:00 PM EDT, down 1.53% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +104.9% · 3-year avg +9.5%/yr · 5-year avg -19.7%/yr
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases.
Biotechnology · San Francisco, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.74
Revenue Est.
$865125.00
Last Quarter Results
EPS
$0.47
vs Estimate
$0.90
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1VIR | $1.96B | $11.60 | -1.53% | +104.88% | -19.71% | N/A | N/A |
| 2AXGN | $1.95B | $36.31 | -2.44% | +107.44% | +19.40% | +15.98% | vs VIR |
| 3INSP | $1.97B | $68.20 | -3.60% | -7.58% | -21.38% | N/A | vs VIR |
| 4FTRE | $1.98B | $20.78 | -1.56% | +122.53% | N/A | N/A | vs VIR |
| 5MLYS | $1.94B | $21.95 | -5.79% | -38.64% | N/A | N/A | vs VIR |
| 6ESTA | $1.92B | $65.29 | -1.78% | +60.08% | -1.56% | N/A | vs VIR |
forward FY estimate
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$238.95M
vs Estimate
$135.88M
Consensus Rating
Based on 9 analysts
Average Price Target
$20.78
+79.1% upside
Low
$15.00
Current
$11.60
High
$30.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.94 | $-0.74 | $-0.51 | 6 |
| Quarter ending Dec 2026 | $-0.77 | $-0.66 | $-0.54 | 5 |
| Quarter ending Mar 2027 | $-1.67 | $-0.51 | $0.15 | 3 |
| Quarter ending Jun 2027 | $-2.12 | $-0.65 | $0.19 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.92 | $-1.77 | $-1.49 | 6 |
| FY 2027 | $-2.94 | $-2.55 | $-2.31 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $14915.00 | $865125.00 | $1.85M | 5 |
| Quarter ending Dec 2026 | $6744.00 | $5.51M | $13.35M | 5 |
| Quarter ending Mar 2027 | $52911.00 | $36.45M | $99.78M | 4 |
| Quarter ending Jun 2027 | $15736.00 | $10.84M | $29.67M | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $236.57M | $245.24M | $256.73M | 7 |
| FY 2027 | $49.69M | $73.59M | $116.39M | 6 |
